Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

interventional study of intravesical chemotherapy and sistemic immunotherapy in NMIBC

Trial Details

NCT ID
NCT06972615
Phase
PHASE2
Sponsor
BLATAM
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • intravesical Chemotherapy docetaxel/gemcitabine
Locations (sample)
  • CABA, Argentina

Key Eligibility Criteria

  • Be willing and able to provide documented informed consent for the trial. The subject may also provide consent for Future Biomedical Research. Howe…
  • Be ≥18 years of age on the day of signing informed consent.
  • Have a histologically confirmed diagnosis of high-risk non-muscle invasive (T1, High Grade Ta and/or CIS) transitional cell carcinoma of the bladde…
  • In subjects who have papillary tumors (Ta and T1), a complete TURBT must have been performed, as characterized by:Attainment of a visually complete…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →